Recursion reports early data for REC-1245, an RBM39 degrader, in solid tumours: no dose-limiting toxicities so far

Recursion/Recursion OS and pipeline

Recursion reported first data from the Phase 1/2 DAHLIA trial of REC-1245, a pill that degrades the RBM39 protein in solid tumours: in 16 patients there were no dose-limiting toxicities and the maximum tolerated dose had not been reached. Side effects were mostly mild (majority Grade 1 or 2 with one Grade 3), with dose escalation continuing toward a Phase 2 dose.

• Phase 1/2 DAHLIA trial in 16 solid-tumour patients; REC-1245 is an RBM39 degrader
• No dose-limiting toxicities observed to date; maximum tolerated dose not yet reached
• Majority of adverse events Grade 1 or 2; most common GI-related (constipation, nausea, vomiting)
• Predictable, dose-dependent pharmacokinetics confirmed; target engagement demonstrated; ongoing dose escalation